Impel NeuroPharma to Present at the Raymond James Human Health Innovation Conference
June 16 2021 - 8:00AM
Impel NeuroPharma, a late-stage biopharmaceutical company focused
on the development and commercialization of transformative
therapies for patients living with central nervous system (CNS)
diseases with high unmet medical needs, today announced that the
Company will present a corporate overview at the Raymond James
Human Health Innovations Conference on Wednesday, June 23, 2021 at
3:20 p.m. ET.
A live webcast, if recorded, of the presentation
can be accessed under “News & Events” in the Investors section
of the Company’s website
at https://investors.impelnp.com/investor-relations. The
archived webcast will be available on the Company’s website shortly
after the event.
About Impel NeuroPharma
Impel NeuroPharma, Inc. is a late-stage
pharmaceutical company focused on utilizing its proprietary
technology to develop and commercialize transformative therapies
for people suffering from diseases with high unmet needs, with an
initial focus on diseases of the CNS. The Company’s strategy is to
rapidly advance its product candidate pipeline that pairs its
proprietary Precision Olfactory Delivery (POD®) system with
well-established therapeutics, including TRUDHESA™ for the acute
treatment of migraine, INP105 for the acute treatment of agitation
and aggression in patients with autism, and INP107 for OFF episodes
in Parkinson’s disease.
Contact
Investor Relations:Christina TartagliaStern
Investor RelationsPhone: (1)
212-362-1200Email: christina.tartaglia@sternir.com
Media Relations:Melyssa WeibleElixir Health
Public RelationsPhone: (1)
201-723-5805Email: mweible@elixirhealthpr.com
Impel Pharmaceuticals (NASDAQ:IMPL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Impel Pharmaceuticals (NASDAQ:IMPL)
Historical Stock Chart
From Jul 2023 to Jul 2024